PharmTech Drug Digest 11.20
News|Articles|November 20, 2014

FDA Requests Comments on Generic Drug Submission Criteria

FDA opens public docket on proposed criteria for “first generic” ANDAs.

FDA is requesting comment on proposed criteria for “first generic” abbreviated new drug application (ANDA) submissions. The agency has established criteria for the review prioritization pursuant to the Generic Drug User Fee Amendments of 2012. FDA says these criteria will allow the agency to prioritize and track ANDA submissions, leading to less industry confusion and consistent identification of “first generic” submissions.

FDA has opened a public docket for comments, and more information can be found on the GDUFA website.

Source: FDA.gov


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.